In recent years, Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as one of the most groundbreaking innovations in cancer treatment. From its remarkable success in treating acute lymphoblastic leukemia (ALL) to its widespread application in lymphoma and multiple myeloma, CAR-T therapy has fundamentally transformed the treatment outcomes of many patients with hematologic malignancies.

However, compared with its rapid success in blood cancers, the clinical development of CAR-T therapy for head and neck cancers, particularly head and neck squamous cell carcinoma (HNSCC), has progressed much more slowly. Although numerous clinical trials are currently underway worldwide, no CAR-T therapy has yet been approved for the treatment of head and neck solid tumors.

Why has CAR-T achieved such extraordinary success in leukemia while facing persistent challenges in head and neck cancers?

Drawing on the latest research findings, DengYueMed provides a comprehensive overview of CAR-T therapy, covering its mechanism of action, the unique characteristics of solid tumors, current development challenges, and future research directions.

---

What Is CAR-T Cell Therapy?

CAR-T therapy is a personalized form of cellular immunotherapy.

Its core principle involves genetically engineering a patient’s own T cells to express Chimeric Antigen Receptors (CARs), enabling them to specifically recognize tumor-associated antigens and directly eliminate cancer cells.

The treatment process typically involves the following steps:

1. Collecting the patient’s peripheral blood T cells
2. Genetically modifying the T cells in the laboratory to express CARs
3. Expanding the engineered CAR-T cells
4. Infusing the CAR-T cells back into the patient
5. Allowing CAR-T cells to continuously recognize and destroy tumor cells

As a “living drug,” CAR-T cells possess the ability to proliferate continuously and provide long-term immune surveillance, enabling durable remission and even functional cures in some patients with hematologic cancers.

---

Why Has CAR-T Been So Successful in Leukemia?

The earliest breakthroughs of CAR-T therapy were achieved in B-cell acute lymphoblastic leukemia (B-ALL), followed by impressive clinical success in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma.

Several biological characteristics explain this remarkable success.

1. Clearly Defined and Stable Therapeutic Targets

Hematologic malignancies possess highly suitable target antigens, including:

• CD19
• BCMA
• CD20
• CD22

These antigens are predominantly expressed on malignant blood cells while showing relatively limited expression in normal tissues.

Consequently, CAR-T cells can selectively target cancer cells while minimizing damage to healthy tissues.

---

2. Easy Access to Tumor Cells

Cancer cells in leukemia and lymphoma circulate within the blood, bone marrow, and lymphatic system.

After infusion, CAR-T cells can rapidly encounter their target cells without having to penetrate complex tissue barriers, resulting in highly efficient tumor cell elimination.

---

3. A Less Immunosuppressive Tumor Microenvironment

Although hematologic malignancies also develop immune escape mechanisms, their immunosuppressive microenvironment is generally less complex than that of most solid tumors.

This allows CAR-T cells to maintain stronger persistence and antitumor activity, contributing to durable clinical responses.

---

In contrast, solid tumors—especially head and neck squamous cell carcinoma—present multiple biological and physical barriers that greatly reduce the effectiveness of CAR-T therapy.

The following section explores why CAR-T therapy remains far more challenging in head and neck cancers than in hematologic malignancies.

---

Why Are Head and Neck Cancers More Difficult to Treat?

Head and neck squamous cell carcinoma (HNSCC) accounts for more than 90% of all head and neck malignancies. Although PD-1 inhibitors, EGFR-targeted therapies, and antibody-drug conjugates (ADCs) have significantly expanded treatment options, patients with recurrent or metastatic HNSCC still face poor long-term outcomes.

When CAR-T cells enter head and neck solid tumors, they encounter several major biological and physical barriers that limit their effectiveness.

---

1. Lack of Ideal Therapeutic Targets

One of the greatest challenges in solid tumors is the absence of highly tumor-specific antigens comparable to CD19, which has been the key to CAR-T success in hematologic malignancies.

Current CAR-T targets under investigation for head and neck cancers include:

• EGFR
• HER2
• HER3
• B7-H3
• MUC1
• CD70
• EpCAM

However, many of these molecules are also expressed in normal epithelial tissues, skin, lungs, and other healthy organs.

As a result, CAR-T cells may attack both cancerous and healthy tissues, leading to on-target, off-tumor toxicity, one of the most significant safety concerns in solid tumor CAR-T development.

Therefore, identifying highly tumor-specific antigens while minimizing toxicity remains one of the biggest challenges facing researchers.

---

2. The Tumor Microenvironment Creates an Immune Barrier

Unlike blood cancers, head and neck tumors possess a highly immunosuppressive tumor microenvironment (TME).

The TME contains numerous cell populations that actively suppress immune responses, including:

• Cancer-associated fibroblasts (CAFs)
• Regulatory T cells (Tregs)
• Myeloid-derived suppressor cells (MDSCs)
• Tumor-associated macrophages (TAMs)

These cells release immunosuppressive cytokines such as:

• Transforming Growth Factor-β (TGF-β)
• Interleukin-10 (IL-10)
• Vascular Endothelial Growth Factor (VEGF)

Together, these factors inhibit CAR-T cell proliferation, reduce cytotoxic activity, and accelerate T-cell exhaustion.

Even when CAR-T cells successfully reach the tumor, this hostile microenvironment can significantly weaken their antitumor effects.

---

3. CAR-T Cells Have Difficulty Penetrating Solid Tumors

Unlike leukemia, where malignant cells circulate freely in the bloodstream, head and neck tumors are protected by dense physical barriers.

CAR-T cells must complete several difficult steps before they can destroy tumor cells:

1. Exit the bloodstream by crossing the vascular endothelium.
2. Migrate through dense extracellular matrix and collagen fibers.
3. Reach the interior of the tumor mass.
4. Survive and remain functionally active within the immunosuppressive environment.

Failure at any of these stages can dramatically reduce therapeutic efficacy.

Researchers are therefore developing novel CAR-T designs capable of improving tumor infiltration and persistence within solid tumors.

---

4. Tumor Heterogeneity Reduces Treatment Effectiveness

Head and neck squamous cell carcinoma exhibits substantial tumor heterogeneity.

Expression of therapeutic targets may differ:

• Between individual patients.
• Between primary and metastatic lesions.
• Even among different regions of the same tumor.

For example:

• Some tumor cells predominantly express EGFR.
• Others may express HER3.
• Some exhibit high levels of B7-H3.
• Others may have little or no expression of these targets.

Consequently, a CAR-T therapy directed against only one antigen may eliminate part of the tumor while leaving antigen-negative cancer cells untouched.

This phenomenon, known as antigen escape, is one of the leading causes of treatment resistance and disease recurrence.

To address this issue, researchers are actively developing:

• Dual-target CAR-T therapies
• Multi-target CAR-T therapies
• Logic-gated CAR-T platforms
• Universal CAR-T systems

These next-generation technologies are designed to recognize multiple tumor antigens simultaneously, reducing the likelihood of immune escape.

---

5. More Complex Safety Considerations

The anatomical structures of the head and neck region are particularly complex.

Critical organs and structures include:

• The airway
• Pharynx
• Larynx
• Major blood vessels
• Cranial nerves
• Salivary glands

CAR-T therapy may induce localized inflammation, immune activation, and tissue edema.

Even moderate swelling around the airway may result in:

• Airway obstruction
• Difficulty breathing
• Emergency airway intervention
• Life-threatening complications

For this reason, investigators developing CAR-T therapies for HNSCC must carefully balance antitumor efficacy with patient safety.

Several newer CAR-T platforms now incorporate controllable or switchable activation mechanisms, allowing physicians to regulate CAR-T activity if severe toxicity develops.

---

Despite these significant challenges, rapid advances in cellular engineering, synthetic biology, and tumor immunology are creating new opportunities for CAR-T therapy in head and neck cancers.

The next section explores the latest research directions and emerging technologies that may overcome these obstacles.

---

Current Research Directions for CAR-T in Head and Neck Cancer

Despite the significant biological barriers associated with solid tumors, researchers and biotechnology companies worldwide continue to advance CAR-T therapy for head and neck malignancies.

Current research is focused on improving target selection, enhancing CAR-T persistence, overcoming the immunosuppressive tumor microenvironment, and reducing treatment-related toxicity.

Several promising strategies are rapidly emerging.

---

Novel Therapeutic Targets

One of the highest priorities in CAR-T development is identifying tumor-associated antigens that are highly expressed on cancer cells but have minimal expression in normal tissues.

Several promising targets are currently under investigation.

B7-H3 (CD276)

B7-H3 is highly expressed in many head and neck squamous cell carcinomas while demonstrating relatively low expression in normal tissues.

High B7-H3 expression has been associated with:

• Increased tumor aggressiveness
• Enhanced metastatic potential
• Poor clinical prognosis
• Immune evasion

Multiple early-phase clinical trials are evaluating B7-H3-targeted CAR-T therapies for solid tumors.

---

CD70

CD70 is another attractive target because its expression is elevated in several advanced solid tumors while remaining limited in healthy tissues.

Potential advantages include:

• Improved tumor specificity
• Reduced off-tumor toxicity
• Synergy with immune checkpoint inhibitors

Several investigational CAR-T products targeting CD70 are currently undergoing clinical evaluation.

---

Claudin 18.2 (CLDN18.2)

Although Claudin 18.2 is primarily associated with gastric and gastroesophageal cancers, researchers are actively exploring its application in selected head and neck cancers with positive biomarker expression.

The remarkable success of Claudin18.2-targeted therapies—including monoclonal antibodies, antibody-drug conjugates (ADCs), and CAR-T therapies—has generated considerable interest in expanding this target to additional solid tumors.

---

HER2 and HER3

HER2 and HER3 remain important investigational targets, particularly in patients whose tumors exhibit overexpression of members of the HER family.

HER3 is of particular interest because it contributes to:

• Tumor progression
• Therapeutic resistance
• PI3K/AKT pathway activation
• Immune escape

Combining HER3-targeted CAR-T therapy with other targeted treatments may further improve antitumor efficacy.

---

Dual-Target and Multi-Target CAR-T Therapies

Because HNSCC demonstrates substantial tumor heterogeneity, single-antigen CAR-T therapy often cannot eliminate every cancer cell.

Researchers are therefore developing:

• Dual-target CAR-T
• Tandem CAR-T
• Multi-specific CAR-T
• Logic-gated CAR-T systems

These next-generation approaches allow engineered T cells to recognize two or more tumor antigens simultaneously.

Potential benefits include:

• Reduced antigen escape
• Broader tumor coverage
• Greater treatment durability
• Improved response rates

Examples include combinations targeting:

• EGFR + HER3
• EGFR + B7-H3
• HER2 + HER3
• CD70 + B7-H3

Multi-target CAR-T platforms are expected to become increasingly important in future solid tumor treatment.

---

CAR-T Combined with Immunotherapy

One major limitation of CAR-T therapy in solid tumors is rapid T-cell exhaustion caused by immune checkpoint signaling.

To overcome this challenge, numerous clinical studies are evaluating combinations of CAR-T therapy with immune checkpoint inhibitors.

The most common strategy combines CAR-T cells with:

• PD-1 inhibitors
• PD-L1 inhibitors
• CTLA-4 inhibitors

Potential advantages include:

• Restoring exhausted CAR-T cell function
• Enhancing T-cell persistence
• Improving immune activation
• Increasing tumor infiltration
• Producing synergistic antitumor responses

Combination immunotherapy represents one of the most active areas of CAR-T research for HNSCC.

---

Regional Delivery Strategies

Traditional CAR-T therapy relies on intravenous infusion.

However, only a limited proportion of infused CAR-T cells successfully reach solid tumors.

Researchers are therefore investigating alternative delivery methods, including:

• Intratumoral injection
• Peritumoral administration
• Regional arterial infusion

Potential advantages include:

• Higher CAR-T concentration within tumors
• Improved tumor infiltration
• Reduced systemic toxicity
• Lower risk of cytokine release syndrome

Regional delivery may become particularly valuable for accessible tumors located in the head and neck.

---

Next-Generation CAR-T Technologies

Rapid advances in synthetic biology have led to the development of several innovative CAR-T platforms.

Armored CAR-T Cells

Armored CAR-T cells are genetically engineered to secrete immune-stimulating cytokines such as:

• IL-12
• IL-15
• IL-18

These cytokines help overcome the immunosuppressive tumor microenvironment while improving CAR-T persistence and function.

---

Controllable CAR-T Systems

Switchable or controllable CAR-T technologies enable physicians to regulate CAR-T activity after infusion.

Potential benefits include:

• Improved safety
• Reduced severe toxicity
• Adjustable treatment intensity
• Better management of adverse events

These systems may be especially important for tumors located near critical organs such as the airway.

---

Universal (Off-the-Shelf) CAR-T

Current CAR-T therapy requires manufacturing a personalized product for every patient.

Universal CAR-T aims to create standardized donor-derived cell products that are immediately available.

Potential advantages include:

• Shorter manufacturing time
• Lower treatment costs
• Improved accessibility
• Faster treatment initiation

Several universal CAR-T products are currently undergoing early clinical evaluation.

---

Future Perspectives

Advances in cellular engineering, gene editing, and tumor immunology continue to create new opportunities for CAR-T therapy in solid tumors.

Future treatment strategies are expected to combine CAR-T therapy with:

• Antibody-drug conjugates (ADCs)
• Bispecific antibodies
• Oncolytic viruses
• Cancer vaccines
• Radiotherapy
• Precision targeted therapies

These combination approaches aim to:

• Improve tumor infiltration
• Remodel the tumor microenvironment
• Reduce immune escape
• Enhance long-term persistence
• Increase overall response rates

In addition, artificial intelligence, multi-omics technologies, single-cell sequencing, and precision biomarker discovery are expected to accelerate patient selection and optimize personalized CAR-T therapy.

Although CAR-T therapy for head and neck cancer remains in clinical development, ongoing innovations suggest that cellular immunotherapy may eventually become an important component of precision treatment for HNSCC.

Current Research Directions for CAR-T in Head and Neck Cancer

Despite these challenges, researchers and biotechnology companies worldwide continue to advance CAR-T therapy for head and neck malignancies.

Current research focuses include:

• Developing novel therapeutic targets, such as B7-H3, CD70, and Claudin 18.2, with greater tumor specificity.
• Dual-target and multi-target CAR-T therapies capable of recognizing multiple tumor antigens to reduce antigen escape.
• Combination immunotherapy, integrating CAR-T cells with PD-1/PD-L1 inhibitors to overcome the immunosuppressive tumor microenvironment.
• Regional delivery strategies, including intratumoral or local administration to increase CAR-T cell concentration at the tumor site while reducing systemic toxicity.
• Next-generation CAR-T technologies, including Armored CAR-T cells, controllable CAR-T platforms, and Universal CAR-T therapies, designed to enhance persistence, functionality, and treatment flexibility.

---

Future Perspectives

Advances in cellular engineering, gene editing, and tumor immunology are creating new opportunities for CAR-T therapy in solid tumors.

In the future, CAR-T therapy is expected to be combined with:

• Antibody-drug conjugates (ADCs)
• Bispecific antibodies
• Oncolytic viruses
• Cancer vaccines
• Radiotherapy

These combination strategies may improve the tumor microenvironment, enhance CAR-T cell infiltration, and reduce immune escape.

In addition, more precise biomarker identification, artificial intelligence-assisted target discovery, and personalized cellular therapies are expected to further accelerate the development of CAR-T treatment for head and neck cancers and other solid tumors.

---

Conclusion

The remarkable success of CAR-T cell therapy in leukemia and other hematologic malignancies has demonstrated the tremendous potential of cellular immunotherapy. However, the complex tumor microenvironment, lack of ideal tumor-specific targets, physical tissue barriers, tumor heterogeneity, and safety concerns have made the application of CAR-T therapy in head and neck solid tumors considerably more challenging.

Although CAR-T has not yet achieved the same level of success in solid tumors as it has in blood cancers, advances in next-generation CAR designs, multi-target strategies, combination therapies, and cellular engineering continue to drive progress in this field.

As more high-quality clinical trial data become available, CAR-T therapy has the potential to become an important component of precision treatment for head and neck cancers, offering new hope and improved outcomes for patients worldwide.

---

References

1. National Comprehensive Cancer Network (NCCN). Head and Neck Cancers Clinical Practice Guidelines.
2. American Society of Clinical Oncology (ASCO). Immunotherapy and Cellular Therapy Updates.
3. European Society for Medical Oncology (ESMO). Head and Neck Cancer Clinical Practice Guidelines.
4. Nature Reviews Clinical Oncology. CAR-T Cell Therapy for Solid Tumors.
5. Nature Reviews Drug Discovery. Next-generation CAR-T Technologies.
6. ClinicalTrials.gov. CAR-T Clinical Trials for Head and Neck Squamous Cell Carcinoma.
7. New England Journal of Medicine (NEJM). CAR-T Therapy in Hematologic Malignancies.
8. Journal for ImmunoTherapy of Cancer (JITC). Emerging CAR-T Strategies in Solid Tumors.

---

About DengYueMed

DengYueMed is a Hong Kong-based pharmaceutical service platform dedicated to helping international patients access innovative medicines, oncology therapies, rare disease treatments, and cross-border medical resources in China.

Our services include:

• Global access to innovative medicines
• Cross-border pharmaceutical sourcing
• Medical information support
• Hospital and specialist referrals
• Assistance with treatment coordination
• International logistics and compliant pharmaceutical supply

Disclaimer: This article is intended for educational and informational purposes only and should not be considered medical advice. Patients should consult qualified healthcare professionals before making any treatment decisions.